OncLive TV

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Anna C. Pavlick, DO, discusses common and uncommon adverse effects with cemiplimab in patients with cutaneous squamous cell carcinoma.

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes. 

Noam VanderWalde, MD, MS, discusses ​where future research ​efforts should focus in rectal cancer. 

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Mohammed M. Milhem, MBBS, discusses the design of an open-label, multicenter phase 1b/2 dose escalation/expansion study with AST-008 in combination with a PD-1 inhibitor, such as pembrolizumab or cemiplimab, in Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Bradley G. Somer, MD, discusses the clinical implications of the FDA approval of atezolizumab in combination with bevacizumab in unresectable or metastatic hepatocellular carcinoma.

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Nilanjan Ghosh, MD, PhD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

John O. Mascarenhas, MD, discusses ongoing clinical trials in myelofibrosis.

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​treatment considerations in triple-negative breast cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.

Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.